.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Healthtrust
Novartis
Dow
Fish and Richardson
Farmers Insurance
Queensland Health
UBS
Teva

Generated: December 16, 2017

DrugPatentWatch Database Preview

Onyx Therap Company Profile

« Back to Dashboard

What is the competitive landscape for ONYX THERAP, and when can generic versions of ONYX THERAP drugs launch?

ONYX THERAP has one approved drug.

There are eleven US patents protecting ONYX THERAP drugs on ONYX THERAP drugs in the past three years.

There are one hundred and sixty-nine patent family members on ONYX THERAP drugs in thirty-five countries and eight supplementary protection certificates in seven countries.

Summary for Onyx Therap

International Patents:169
US Patents:11
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► SubscribeYY► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► SubscribeYY► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ONYX THERAP drugs

Drugname Dosage Strength Tradename Submissiondate
carfilzomibFor Injection60 mg/vialKYPROLIS7/20/2016

Non-Orange Book Patents for Onyx Therap

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,198,270Compounds for proteasome enzyme inhibition► Subscribe
8,088,741Compounds for enzyme inhibition► Subscribe
8,324,174Compounds for enzyme inhibition► Subscribe
8,207,124Compounds for enzyme inhibition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Onyx Therap Drugs

Country Document Number Estimated Expiration
Japan6081964► Subscribe
Cyprus1114025► Subscribe
Japan2014221805► Subscribe
Spain2510840► Subscribe
Australia2012203602► Subscribe
Australia2005295183► Subscribe
Israel183607► Subscribe
Israel178400► Subscribe
New Zealand603739► Subscribe
European Patent Office2266999► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Onyx Therap Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016010,C1781688Lithuania► SubscribePRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119
90013-6Sweden► SubscribePRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123
0160008 00189Estonia► SubscribePRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015
C0017France► SubscribePRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123
015Luxembourg► SubscribePRODUCT NAME: CARFILZOMIB EVENTUELLEMENT SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151123
2016 00014Denmark► SubscribePRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1060 20151123
2016010Lithuania► SubscribePRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119
0805Netherlands► SubscribePRODUCT NAME: CARFILZOMIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/15/1060 20151123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cantor Fitzgerald
Johnson and Johnson
Fish and Richardson
Julphar
Harvard Business School
Medtronic
US Department of Justice
Moodys
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot